Publications
Detailed Information
Efficacy of pemetrexed-based chemotherapy in comparison to non-pemetrexed-based chemotherapy in advanced, ALK plus non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jo, Jaemin | - |
dc.contributor.author | Kim, Se Hyun | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Lee, Juhyun | - |
dc.contributor.author | Kim, Miso | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Chung, Jin-Haeng | - |
dc.contributor.author | Jeon, Yoon Kyung | - |
dc.contributor.author | Lee, Jong Seok | - |
dc.date.accessioned | 2020-04-27T11:05:44Z | - |
dc.date.available | 2020-04-27T11:05:44Z | - |
dc.date.created | 2019-04-30 | - |
dc.date.issued | 2018-03 | - |
dc.identifier.citation | Yonsei Medical Journal, Vol.59 No.2, pp.202-210 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.other | 73419 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165245 | - |
dc.description.abstract | Purpose: Previous retrospective studies suggest that anaplastic lymphoma kinase (ALK) mutation-positive (ALK+) non-small cell lung cancer (NSCLC) patients are sensitive to pemetrexed. To determine its efficacy, we retrospectively evaluated clinical outcomes of pemetrexed-based chemotherapy in patients with ALK+ NSCLC. Materials and Methods: We identified 126 patients with advanced, ALK+ NSCLC who received first-line cytotoxic chemotherapy. We compared response, progression-free survival (PFS), and overall survival (OS) rates according to chemotherapy regimens. Furthermore, we evaluated intracranial time to tumor progression (TTP) and proportion of ALK+ cells as prognostic factors. Results: Forty-eight patients received pemetrexed-based chemotherapy, while 78 received other regimens as first-line treatment. The pemetrexed-based chemotherapy group showed superior overall response (44.7% vs. 14.3%, p<0.001) and disease control (85.1% vs. 62.3%, p=0.008) rates. The pemetrexed-based chemotherapy group also exhibited longer PFS (6.6 months vs. 3.8 months, p<0.001); OS rates were not significantly different. The lack of exposure to second-generation ALK inhibitors and intracranial metastasis on initial diagnosis were independent negative prognostic factors of OS. Intracranial TTP was similar between the treatment groups (32.7 months vs. 35.7 months, p=0.733). Patients who harbored a greater number of ALK+ tumor cells (>= 70%) showed prolonged OS on univariate analysis (not reached vs. 44.8 months, p=0.041), but not on multivariate analysis (hazard ratio: 0.19, 95% confidence interval: 0.03-1.42; p=0.106). Conclusion: Pemetrexed-based regimens may prolong PFS in patients with ALK+ NSCLC as a first-line treatment, but are not associated with prolonged OS. Exposure to second-generation ALK inhibitors may improve OS rates in patients with ALK+ NSCLC. | - |
dc.language | 영어 | - |
dc.publisher | 연세대학교의과대학 | - |
dc.title | Efficacy of pemetrexed-based chemotherapy in comparison to non-pemetrexed-based chemotherapy in advanced, ALK plus non-small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.contributor.AlternativeAuthor | 전윤경 | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 정진행 | - |
dc.contributor.AlternativeAuthor | 이종석 | - |
dc.identifier.doi | 10.3349/ymj.2018.59.2.202 | - |
dc.citation.journaltitle | Yonsei Medical Journal | - |
dc.identifier.wosid | 000425361900006 | - |
dc.identifier.scopusid | 2-s2.0-85042099444 | - |
dc.citation.endpage | 210 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 202 | - |
dc.citation.volume | 59 | - |
dc.identifier.sci | 000425361900006 | - |
dc.identifier.kciid | ART002316223 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.contributor.affiliatedAuthor | Chung, Jin-Haeng | - |
dc.contributor.affiliatedAuthor | Jeon, Yoon Kyung | - |
dc.contributor.affiliatedAuthor | Lee, Jong Seok | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | THYMIDYLATE SYNTHASE | - |
dc.subject.keywordPlus | BRAIN METASTASES | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | CRIZOTINIB | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | GEMCITABINE | - |
dc.subject.keywordPlus | PERCENTAGE | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordAuthor | Anaplastic lymphoma kinase | - |
dc.subject.keywordAuthor | carcinoma | - |
dc.subject.keywordAuthor | non-small-cell lung | - |
dc.subject.keywordAuthor | pemetrexed | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.